News und Analysen

On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices

Megacap technology stocks are starting to look a little expensive, especially after recent moves in stocks like Nvidia (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD). It's tough to know

Any pharmaceutical company as large and sprawling as AbbVie (NYSE: ABBV) never stops being busy, from pushing investigational drugs along the development pipeline to shipping blockbuster medications

Shares of Intellia Therapeutics (NASDAQ: NTLA), a small-cap biotech company, are up by 63% this year. The company is benefiting from substantial clinical progress, and judging by price targets set

Pfizer (NYSE: PFE) has a huge 6.3% dividend yield. That's actually a lot lower than it was not too long ago, thanks to a large stock advance in recent days based on news. But Pfizer's price rebound

If x is good, isn't 2x even better? Usually. Granted, there can be too much of a good thing. For example, you might regret eating two giant helpings of ice cream rather than one. However, in many

Nvidia is arguably the king of Wall Street these days. As the maker of high-performing graphics processing units (GPUs) that power artificial intelligence (AI) programs and large language models

Summit Financial Wealth Advisors, LLC initiated a new position in First Trust Enhanced Short Maturity ETF (NASDAQ:FTSM), acquiring approximately $20.03 million in shares as of Q3 2025, according to

In this video, I will discuss recent updates regarding Advanced Micro Devices (NASDAQ: AMD) and OpenAI. Watch the short video to learn more, consider subscribing, and click the special offer link

Pfizer (NYSE: PFE) made a deal with the White House to avoid paying tariffs on imported products.

*Stock prices used were the afternoon prices of Oct. 3, 2025. The video was published on Oct. 5

Pfizer (NYSE: PFE) continues to lag the market. Over the past few years, the company has generally reported declining revenue and profits, resulting in a substantial decline in market value. The

Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present. The good

Even in hindsight, it would have been difficult to predict Summit Therapeutics' (NASDAQ: SMMT) exceptional rise over the past three years. The company's shares have skyrocketed by more than 1,500%

Pfizer (NYSE: PFE) is one of the largest healthcare companies in the world. It was founded in 1849 and has since become an iconic name in healthcare.

It has developed many medicines over the years

Shares of Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical company, shot 90.6% higher in October, according to data from S&P Global Market Intelligence. Investors have been increasingly

Equity markets experienced significant volatility this year. Many investors feared that President Donald Trump's aggressive trade policies would plunge the economy into a recession and lead to a

Major market indexes such as the S&P 500 declined in the first few months of the year, but have since rebounded significantly. In contrast, biotech giant Amgen (NASDAQ: AMGN) started the year

Before the market open on the last trading day of the week, two analysts tracking Genmab (NASDAQ: GMAB) stock felt compelled to raise their price targets on the biotech. This double-barreled blast

St. Louis Financial Planners Asset Management, LLC initiated a new stake in AbbVie (NYSE:ABBV), acquiring 14,630 shares for an estimated $3.39 million in Q3 2025.

According to a Securities and

St. Louis Financial Planners Asset Management, LLC disclosed in a Thursday filing with the SEC that it sold shares of AT&T worth an estimated $3.3 million in the third quarter.

According to a

Shares in Eli Lilly (NYSE: LLY) had risen 13.2% in the week to Friday morning. The move comes at a time when peer Pfizer announced a deal with the Trump administration that gave that pharmaceutical

The biggest risks facing pharmaceutical companies in recent times haven't had to do with clinical trials or winning regulatory approval. Instead, investors have worried about President Donald

Explore the exciting world of Zoetis (NYSE: ZTS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends

Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early

In today's video, I discuss recent updates impacting Intel (NASDAQ: INTC), Advanced Micro Devices (NASDAQ: AMD), and Nvidia (NASDAQ: NVDA). To learn more, check out the short video, consider